Biological
Lymphocytes, Tumor-Infiltrating clinical trials
Keep track of what changes. Save the Lymphocytes, Tumor-Infiltrating studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
42 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 31
Shanghai Juncell Therapeutics (7) · Inge Marie Svane (5) · Essen Biotech (5) · Udai Kammula (3) · National Cancer Institute (NCI) (2) · Christian Hinrichs (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · TILT Biotherapeutics Ltd. (1)
Often tested with
Tested in the same studies.
Therapeutic Tumor Infiltrating Lymphocytes (38) · Cyclophosphamide (5) · Fludarabine (5) · Pembrolizumab (4) · Interleukin-2 (3) · Aldesleukin (2) · Igrelimogene litadenorepvec (1) · Vemurafenib (1)
Studies
Open first, then newest update. How each study uses Lymphocytes, Tumor-Infiltrating is read from its arms, and is right about nine times in ten.
Testing it · 42
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingPhase 2National Cancer Institute (NCI)NCT02133196Written as Young TIL
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersRecruitingPhase 1/2Christian HinrichsNCT05639972Written as E7 TCR-T cells
- Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06047977Written as Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
- Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05681780Written as Tumor-infiltrating Lymphocytes (TIL)
- A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)RecruitingEarly Phase 1Shanghai Juncell TherapeuticsNCT04960072Written as Tumor Infiltrating Lymphocytes (TIL)
- Study of GC101 TIL in Brain Glioma (Soochow2)RecruitingEarly Phase 1Shanghai Juncell TherapeuticsNCT04943913Written as Tumor Infiltrating Lymphocytes (TIL)
- A Clinical Study on TIL for the Treatment of Advanced Solid TumorsRecruitingEarly Phase 1Shanghai Juncell TherapeuticsNCT05087745Written as Tumor Infiltrating Lymphocytes
- A Study of GC101 TIL in Advanced Solid Tumors (TR)RecruitingEarly Phase 1Shanghai Juncell TherapeuticsNCT04967833Written as Tumor Infiltrating Lymphocytes (TIL)
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersRecruitingPhase 2Christian HinrichsNCT05686226Written as E7 TCR-T cells
- A Study of GC101 TIL in Advanced Breast Cancer (10hospital)RecruitingEarly Phase 1Shanghai Juncell TherapeuticsNCT05142475Written as Tumor Infiltrating Lymphocytes (TIL)
- A Study of GC101 TIL in Advanced Melanoma (10hospital)RecruitingEarly Phase 1Shanghai Juncell TherapeuticsNCT05098184Written as Tumor Infiltrating Lymphocyte
- A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)RecruitingEarly Phase 1Shanghai Juncell TherapeuticsNCT05098197Written as Tumor Infiltrating Lymphocyte
- Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint InhibitorsNot yet recruitingNot applicableSamsung Medical CenterNCT07028008Written as tumor-infiltrating lymphocyte (TIL)
- TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerRecruitingPhase 1/2Essen BiotechNCT06532812Written as Tumor Infiltrating Lymphocytes (TIL)
- TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerRecruitingPhase 1/2Essen BiotechNCT06532799Written as Tumor Infiltrating Lymphocytes (TIL)
- TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and MeningiomasRecruitingPhase 1/2Essen BiotechNCT06640582Written as Tumor Infiltrating Lymphocytes (TIL)
- Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum CancerRecruitingPhase 1/2Essen BiotechNCT06530303Written as Tumor Infiltrating Lymphocytes (TIL)
- TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerRecruitingPhase 1/2Essen BiotechNCT06538012Written as Tumor Infiltrating Lymphocytes (TIL)
- Immunotherapy for the Treatment of Advanced Solid TumorRecruitingPhase 1/2Tongji HospitalNCT03658785Written as TIL
- Study on TIL for the Treatment of r/r Gynecologic TumorsRecruitingPhase 1Shanghai 10th People's HospitalNCT04766320Written as Tumor Infiltrating Lymphocytes (TIL)
See all 42 studies that test Lymphocytes, Tumor-Infiltrating →
Given in every arm · 15 — Lymphocytes, Tumor-Infiltrating is usual care beside what is tested
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT01174121Written as Young TIL
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingPhase 2National Cancer Institute (NCI)NCT02621021Written as young TIL
- TIL Therapy for Patients With Advanced Solid TumorsNot yet recruitingPhase 1NeogenTCNCT06107894Written as Tumor-infiltrating lymphocytes
- Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsRecruitingPhase 2Sheba Medical CenterNCT03166397Written as TIL
- Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue SarcomaCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT04052334Written as TIL
- Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...CompletedPhase 2National Cancer Institute (NCI)NCT01319565Written as Young TIL
- Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic MelanomaCompletedEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT02652455Written as TIL Infusion
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedPhase 1/2Inge Marie SvaneNCT04611126Written as Tumor Infiltrating Lymphocytes infusion
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT01993719Written as Young TIL
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedEarly Phase 1Yale UniversityNCT03526185Written as Tumor Infiltrating Lymphocytes
- Adoptive T Cell Therapy in Patients With Recurrent Ovarian CancerStatus unknownPhase 1/2Leiden University Medical CenterNCT04072263Written as Tumor Infiltrating Lymphocytes (TIL)
- The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) TrialCompletedPhase 1University Health Network, TorontoNCT03158935Written as Tumor-Infiltrating Lymphocytes (TILs)
- Vemurafenib and White Blood Cell Therapy for Advanced MelanomaTerminatedPhase 1National Cancer Institute (NCI)NCT01585415Written as Young TIL
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated CancersCompletedPhase 2National Cancer Institute (NCI)NCT01585428Written as Young TIL
- Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic MelanomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT01369888Written as Tumor Infiltrating Lymphocytes